tirzepatide fda approval 2022 vs. Retatrutide: Key Differences Explained FDA Approves Mounjaro (tirzepatide) Injection

doi: 10.1016/B978-0-12-381517-0.00015-1

Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding general personal health, medical conditions, or drugs or medications, and before commencing or discontinuing any course of treatment, drug, or medication

the Pen is expired (EXP) or looks damaged

This level of ongoing supervision matters because tirzepatide is not a one-size-fits-all medication

The SURPASS trials (studying tirzepatide for diabetes) showed approximately 5 to 13 percent weight loss over 40 to 52 weeks, compared to 16 to 22.5 percent in the SURMOUNT obesity trials